NCT07173933View on ClinicalTrials.gov

Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of GC310 Injection in Patients With Wilson's Disease (WD)

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

October 31, 2027

Conditions
Wilson Disease
Interventions
GENETIC

GC310

GC310 is an adeno-associated virus 5 (AAV5) vector delivering a functional copy of the truncated human ATP7B gene

Trial Locations (1)

100005

Peking Union Medical College, Beijing

All Listed Sponsors
lead

GeneCradle Inc

INDUSTRY

NCT07173933 - Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of GC310 Injection in Patients With Wilson's Disease (WD) | Biotech Hunter | Biotech Hunter